# Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

> **NCT03245424** · — · APPROVED_FOR_MARKETING · sponsor: **Agios Pharmaceuticals, Inc.**

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed Adult AML
- Relapsed Pediatric AML

## Interventions

- **DRUG:** ivosidenib (AG-120)

## Key facts

- **NCT ID:** NCT03245424
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245424, "Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03245424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*